Literature DB >> 23311288

Hypoxia-selective O6-alkylguanine-DNA alkyltransferase inhibitors: design, synthesis, and evaluation of 6-(benzyloxy)-2-(aryldiazenyl)-9H-purines as prodrugs of O6-benzylguanine.

Rui Zhu1, Raymond P Baumann, Philip G Penketh, Krishnamurthy Shyam, Alan C Sartorelli.   

Abstract

O(6)-Alkylguanine-DNA alkyltransferase (AGT) is a DNA repair protein which removes alkyl groups from the O-6 position of guanine, thereby providing strong resistance to anticancer agents which alkylate this position. The clinical usefulness of these anticancer agents would be substantially augmented if AGT could be selectively inhibited in tumor tissue, without a corresponding depletion in normal tissue. We report the synthesis of a new AGT inhibitor (5c) which selectively depletes AGT in hypoxic tumor cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23311288      PMCID: PMC3722860          DOI: 10.1021/jm301804p

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  21 in total

1.  Role of O6-alkylguanine-DNA alkyltransferase in the cytotoxic activity of cloretazine.

Authors:  Kimiko Ishiguro; Krishnamurthy Shyam; Philip G Penketh; Alan C Sartorelli
Journal:  Mol Cancer Ther       Date:  2005-11       Impact factor: 6.261

2.  Substituted O6-benzylguanine derivatives and their inactivation of human O6-alkylguanine-DNA alkyltransferase.

Authors:  M Y Chae; M G McDougall; M E Dolan; K Swenn; A E Pegg; R C Moschel
Journal:  J Med Chem       Date:  1994-02-04       Impact factor: 7.446

3.  Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.

Authors:  Jennifer A Quinn; James Pluda; M Eileen Dolan; Shannon Delaney; Richard Kaplan; Jeremy N Rich; Allan H Friedman; David A Reardon; John H Sampson; O Michael Colvin; Michael M Haglund; Anthony E Pegg; Robert C Moschel; Roger E McLendon; James M Provenzale; Sridharan Gururangan; Sandra Tourt-Uhlig; James E Herndon; Darell D Bigner; Henry S Friedman
Journal:  J Clin Oncol       Date:  2002-05-01       Impact factor: 44.544

4.  Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.

Authors:  R L Schilsky; M E Dolan; D Bertucci; R B Ewesuedo; N J Vogelzang; S Mani; L R Wilson; M J Ratain
Journal:  Clin Cancer Res       Date:  2000-08       Impact factor: 12.531

5.  Design of a hypoxia-activated prodrug inhibitor of O6-alkylguanine-DNA alkyltransferase.

Authors:  Rui Zhu; Helen A Seow; Raymond P Baumann; Kimiko Ishiguro; Philip G Penketh; Krishnamurthy Shyam; Alan C Sartorelli
Journal:  Bioorg Med Chem Lett       Date:  2012-08-10       Impact factor: 2.823

6.  Synthesis of Aryl Nitroso Derivatives by tert-Butyl Hypochlorite Oxidation in Homogeneous Media. Intermediates for the Preparation of High-Hyperpolarizability Chromophore Skeletons.

Authors:  M. H. Davey; V. Y. Lee; R. D. Miller; T. J. Marks
Journal:  J Org Chem       Date:  1999-06-25       Impact factor: 4.354

7.  1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): II. Role of O6-alkylguanine-DNA alkyltransferase in cytotoxicity.

Authors:  R P Baumann; K Shyam; P G Penketh; J S Remack; T P Brent; A C Sartorelli
Journal:  Cancer Chemother Pharmacol       Date:  2003-12-17       Impact factor: 3.333

8.  Generation of oxygen deficiency in cell culture using a two-enzyme system to evaluate agents targeting hypoxic tumor cells.

Authors:  Raymond P Baumann; Philip G Penketh; Helen A Seow; Krishnamurthy Shyam; Alan C Sartorelli
Journal:  Radiat Res       Date:  2008-11       Impact factor: 2.841

9.  Development of an O(6)-alkylguanine-DNA alkyltransferase assay based on covalent transfer of the benzyl moiety from [benzene-3H]O(6)-benzylguanine to the protein.

Authors:  Kimiko Ishiguro; Krishnamurthy Shyam; Philip G Penketh; Alan C Sartorelli
Journal:  Anal Biochem       Date:  2008-08-20       Impact factor: 3.365

Review 10.  O6-benzylguanine and its role in chemotherapy.

Authors:  M E Dolan; A E Pegg
Journal:  Clin Cancer Res       Date:  1997-06       Impact factor: 12.531

View more
  5 in total

1.  Synthesis and SAR studies of novel 6,7,8-substituted 4-substituted benzyloxyquinolin-2(1H)-one derivatives for anticancer activity.

Authors:  Yi-Fong Chen; Yi-Chien Lin; Susan L Morris-Natschke; Chen-Fang Wei; Ting-Chen Shen; Hui-Yi Lin; Mei-Hua Hsu; Li-Chen Chou; Yu Zhao; Sheng-Chu Kuo; Kuo-Hsiung Lee; Li-Jiau Huang
Journal:  Br J Pharmacol       Date:  2015-01-13       Impact factor: 8.739

Review 2.  Hypoxia-activated prodrugs and redox-responsive nanocarriers.

Authors:  Yun Zeng; Jingwen Ma; Yonghua Zhan; Xinyi Xu; Qi Zeng; Jimin Liang; Xueli Chen
Journal:  Int J Nanomedicine       Date:  2018-10-18

3.  Reductive Activity and Mechanism of Hypoxia- Targeted AGT Inhibitors: An Experimental and Theoretical Investigation.

Authors:  Weinan Xiao; Guohui Sun; Tengjiao Fan; Junjun Liu; Na Zhang; Lijiao Zhao; Rugang Zhong
Journal:  Int J Mol Sci       Date:  2019-12-13       Impact factor: 5.923

Review 4.  Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.

Authors:  Roger M Phillips
Journal:  Cancer Chemother Pharmacol       Date:  2016-01-25       Impact factor: 3.333

5.  Two-Step, One-Pot Synthesis of Visible-Light-Responsive 6-Azopurines.

Authors:  Dušan Kolarski; Wiktor Szymanski; Ben L Feringa
Journal:  Org Lett       Date:  2017-09-11       Impact factor: 6.072

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.